The History of Limosilactobacillus reuteri
by Mary Ferrari
“Limosilactobacillus reuteri (formerly Lactobacillus reuteri) is one of the best-studied beneficial bacteria naturally associated with humans. This early transfer is closely linked to milk biology. “
Limosilactobacillus reuteri
Limosilactobacillus reuteri (formerly Lactobacillus reuteri) is one of the best-studied beneficial bacteria naturally associated with humans. It has likely co-evolved with humans for thousands of years as a normal inhabitant of the gastrointestinal tract, particularly the small intestine, where it helps maintain a healthy microbial ecosystem. In addition to colonizing the gut, L. reuteri is naturally found in breast milk, the skin, and the urinary tract. During breastfeeding, it is transferred from mother to infant, helping establish the developing gut microbiome during the critical first months of life.
This early transfer is closely linked to milk biology. Humans do not produce lactose throughout the body; instead, lactose is synthesized exclusively in the mammary glands during lactation as the primary carbohydrate in breast milk. Its biological purpose is to nourish the growing infant while also providing a substrate for beneficial gut microbes. Humans produce lactase—the enzyme that digests lactose into glucose and galactose for absorption—not lactose itself, except within the mammary gland during milk production. Infants naturally produce high levels of lactase, allowing them to efficiently digest breast milk during early life. However, in approximately two-thirds of the world’s population, lactase production declines after weaning, resulting in adult-type lactose intolerance. A genetic adaptation known as lactase persistence evolved independently in several dairy-farming populations of Europe, Africa, and the Middle East, allowing continued digestion of lactose throughout adulthood. This evolutionary relationship between milk, lactose, and beneficial microbes such as L. reuteri highlights the intimate connection between mammalian nutrition and the development of the infant microbiome.
Historically, L. reuteri was a common member of the human microbiome. Modern studies, however, suggest that its prevalence has declined dramatically in industrialized countries, where only about 10–20% of adults naturally harbor the organism. Researchers believe this decline may be related to widespread antibiotic use, cesarean deliveries, reduced breastfeeding, improved sanitation, dietary changes, and the consumption of highly processed foods, all of which have altered the composition of the modern gut microbiome.
One reason L. reuteri has attracted significant scientific interest is its remarkable ability to survive the harsh conditions of the gastrointestinal tract. Unlike many transient probiotic organisms, L. reuteri is a true human symbiont that has adapted to tolerate stomach acid and bile salts, allowing it to temporarily colonize the intestine after consumption. It produces reuterin, a broad-spectrum antimicrobial compound that suppresses many pathogenic bacteria, fungi, and other harmful microorganisms while helping preserve a balanced intestinal microbiota. Research has also shown that L. reuteri strengthens the intestinal barrier, supports tight junction integrity, and promotes regulatory T cells that help control excessive inflammation and maintain immune tolerance.
Interest in L. reuteri expanded considerably after strains isolated from human breast milk, particularly DSM 17938, demonstrated benefits for infant digestive health, including reducing colic and supporting normal gastrointestinal development. Today, these strains are widely incorporated into probiotic supplements and fermented dairy products. Although today supplemental L. reuteri typically colonizes the intestine only transiently, regular consumption can help replenish this increasingly uncommon member of the modern human microbiome.
Most probiotics do not create a long term change in the modern gut microbiome after you stop using them. Once supplementation ends, the microbial ecosystem undergoes a “reshuffling” period and generally reverts close to its pre-supplement baseline. The gut microbiome operates on a strict “supply and demand” ecology. No food, no niche. Without it, these bacteria lose their competitive advantage and are outcompeted by other microbes feeding on your normal daily diet. Unlike an infant’s highly malleable, blank-slate gut, an adult’s microbiome is an entrenched, stable ecosystem. And unlike the healthy breastfed stable adult eco system with evidence of longevity due to proper formation, it actively resists permanent colonization by new strains or massive shifts in existing populations, pulling the environment back to its established equilibrium over time. The one major exception is a specific strain of probiotic that can utilize all HMO’s and includes the entire genetic machinery to helping establish a more permanent residency, that is, the one big exception: permanent engraftment.
As beneficial as this is according to most scientists no supplement or diet will likely ever replace the complexity of breast milk or the thousands of years of coevolution with our ancestral diets which relied on fermented foods and traditional methods of preservation rather than refrigeration and preservatives that preceded the modern era of infant formula feeding (1866-2026) and other processed foods.
Reclassification
In 2020, advances in bacterial genomics led to a major reclassification of the large Lactobacillus genus. As a result, Lactobacillus reuteri was renamed Limosilactobacillus reuteri. This taxonomic change reflected improved understanding of evolutionary relationships among lactic acid bacteria rather than any change in the organism itself.
The same taxonomic revision also placed Limosilactobacillus murinus within the new genus. Although L. murinus and L. reuteri are closely related, they are distinct species with very different biological functions. Recent studies illustrate that closely related bacteria can produce dramatically different effects on human health. Certain strains of L. murinus have been associated with altered metabolism and neuroinflammation in experimental models of autism spectrum disorder, whereas selected strains of L. reuteri exhibit anti-inflammatory properties, promote production of the inhibitory neurotransmitter GABA, reduce activation of inflammatory CD4⁺ T cells, and improve behavioral outcomes in preclinical studies.
These discoveries have transformed L. reuteri from being viewed simply as a probiotic into a promising live biotherapeutic organism. Current research is exploring its potential role not only in gastrointestinal health but also in immune regulation, gut barrier function, and the gut-brain axis, with possible applications for inflammatory, metabolic, and neurodevelopmental disorders. Although much of this work remains experimental, L. reuteri has become one of the leading examples of how restoring beneficial members of the human microbiome may influence health far beyond the digestive system.
Source:
Role of Lactobacillus reuteri in Human Health and Diseases
Limosilactobacillus reuteri – a probiotic gut commensal with contextual impact on immunity
Persistence of Lactobacillus reuteri DSM17938 in the human intestinal tract:
Breast Milk, a Source of Beneficial Microbes and Associated Benefits for Infant Health
Evolution of lactase persistence: an example of human niche construction
An Evolutionary Whodunit: How Did Humans Develop Lactose Tolerance?
Gut Bacteria and Immune Cells May Drive Autism
Real-world of Limosilactobacillus reuteri in mitigation of acute experimental colitis
2026
One of the most important findings involved oxytocin, often called the “social bonding hormone.” Oxytocin is produced in the hypothalamus and plays a critical role in social behavior, emotional attachment, and communication. Previous research has shown that oxytocin signaling can be disrupted in some animal models of autism. In this study, maternal separation reduced normal oxytocin activity, but administration of L. reuteri restored oxytocin expression within the paraventricular nucleus (PVN) of the hypothalamus, suggesting that the probiotic influenced brain function through an oxytocin-dependent pathway.
The researchers also examined two regions of the medial prefrontal cortex, an area involved in decision-making, emotional regulation, and social behavior. Maternal separation produced abnormal structural changes in these brain regions, with the infralimbic cortex becoming enlarged and containing excess neurons, while the anterior cingulate cortex became smaller and lost neurons. These alterations were largely normalized in the animals receiving L. reuteri, suggesting that changes in the gut microbiome may influence brain development and neural organization.
Taken together, the findings suggest that L. reuteri did far more than simply alter the intestinal microbiome. It appeared to influence communication along the gut-brain axis, restoring beneficial gut bacteria, increasing oxytocin production, normalizing brain structure, and improving autism-like behaviors. Although these findings are limited to an animal model, they provide evidence that certain probiotic strains may affect neurological function by interacting with the immune system, the nervous system, and the intestinal microbiome.
Is Autism a T Cell Mediated Disease?
by Mary Ferrari
“Together these studies support a unified model of ASD in which intestinal dysbiosis influences immune maturation, particularly CD4⁺ T cells and regulatory T cells, leading to chronic low-grade inflammation that extends beyond the gut and affects the brain.”
Autism Spectrum Disorder, the Gut Microbiome, and Immune Regulation
Over the past two decades, research has transformed our understanding of autism spectrum disorder (ASD). Once viewed primarily as a neurodevelopmental condition driven by genetics, ASD is now recognized as a complex disorder involving interactions between genetics, the immune system, the gut microbiome, and the brain. Mounting evidence indicates that alterations in the intestinal microbiota can influence immune development, neuroinflammation and behavior through the gut-brain axis. This growing body of research has opened new avenues for understanding ASD and has generated interest in microbiome-based therapies.
Early observations showed that gastrointestinal symptoms are common in children with ASD, affecting an estimated 30–70% of patients. Researchers also found that children with ASD frequently exhibit immune abnormalities, including elevated inflammatory cytokines, altered T-cell populations, and reduced immune regulation. These findings suggested that the immune system might serve as the biological bridge connecting the intestinal microbiome with the central nervous system. As studies progressed, investigators discovered that the composition of the gut microbiota differs significantly between individuals with ASD and neurotypical controls. Although results vary among studies, recurring patterns include increased abundances of Clostridium, Lactobacillus, and Faecalibacterium, together with reductions in Bifidobacterium, Enterococcus, and Streptococcus. These microbial shifts are thought to alter microbial metabolite production, intestinal barrier function, and immune signaling, all of which may influence brain development and behavior.
A major milestone came when researchers demonstrated that gut microbes could directly influence behavior. In groundbreaking fecal microbiota transfer experiments, gut microbiota collected from individuals with ASD were transplanted into germ-free mice. Remarkably, these recipient mice developed social deficits, repetitive behaviors, and other ASD-like characteristics despite having no genetic predisposition for autism.
These experiments provided some of the strongest evidence to date that the gut microbiome itself contributes to disease rather than merely reflecting it. The findings also implicated microbial metabolites as important mediators of communication between the gut and the brain.
Building on these discoveries, a 2025 study published in Nature Communications provided one of the most detailed descriptions of the gut-immune-brain axis in autism. Using germ-free BTBR mice, a well-established mouse model of ASD, investigators found that the complete absence of intestinal microbes substantially improved several autism-associated behaviors, including repetitive behaviors, anxiety-like behavior, and impaired social memory. These behavioral improvements were accompanied by reduced activation of inflammatory CD4⁺ T cells within the brain and decreased neuroinflammation. Importantly, depletion of CD4⁺ T cells alone produced many of the same behavioral improvements, demonstrating that T-cell-mediated inflammation serves as a critical link between gut microbes and neurological function.
The investigators also identified microbial metabolites that may contribute to neurological dysfunction. Mice exhibiting ASD behaviors had elevated glutamate levels, an increased glutamate-to-GABA ratio, and increased concentrations of 3-hydroxyglutaric acid, a neurotoxic metabolite capable of disrupting excitatory and inhibitory neurotransmission. They further identified Limosilactobacillus murinus as a bacterium capable of promoting these metabolic changes and driving neuroinflammation. Conversely, administration of a selected Limosilactobacillus reuteri probiotic candidate reduced inflammatory responses, normalized neurotransmitter balance, lowered activation of brain-resident CD4⁺ T cells, and significantly improved ASD-associated behaviors. These findings suggest that carefully selected probiotic strains may eventually become adjunctive therapies capable of modifying disease mechanisms rather than simply treating symptoms.
Interest in probiotic therapy has therefore grown substantially. Several probiotic strains have demonstrated encouraging results in animal studies, including Limosilactobacillus reuteri ATCC PTA 6475, L. reuteri RC-14, and Bacteroides fragilis NCTC 9343. Early human clinical studies using L. reuteri ATCC PTA 6475 and DSM 17938 have also shown promise, although larger randomized clinical trials are still needed before firm conclusions can be drawn. As the prevalence of ASD continues to rise worldwide, identifying safe microbiome-directed interventions has become an important research priority.
Regulatory T cells
The role of regulatory T cells (Tregs) has also received increasing attention. These specialized immune cells maintain immune tolerance by suppressing excessive inflammatory responses and preventing inappropriate immune activation. In 2026, investigators at the UC Davis MIND Institute examined Tregs in children with ASD and found widespread abnormalities in both Treg phenotype and gene expression. Children with ASD exhibited altered expression of genes involved in immune signaling, metabolism, chromatin organization, and inflammatory regulation. Those with persistent gastrointestinal symptoms demonstrated particularly pronounced reductions in gut-homing activated Treg populations, suggesting impaired immune regulation within the intestinal environment. Lower Treg frequencies also correlated with more severe behavioral abnormalities, supporting the concept that defective immune regulation contributes to both gastrointestinal dysfunction and neurological symptoms in ASD.
Collectively, these studies support a unified model of ASD in which intestinal dysbiosis influences immune maturation, particularly CD4⁺ T cells and regulatory T cells, leading to chronic low-grade inflammation that extends beyond the gut and affects the brain. Microbial metabolites further influence neurotransmitter balance, microglial activation, and neuronal function, contributing to behavioral abnormalities. While the microbiome might not explain every case of autism, it has emerged as an important biological factor capable of modifying disease severity and potentially serving as a therapeutic target. Future treatments may combine dietary interventions, probiotics, prebiotics, postbiotics, and microbiome restoration strategies to support immune regulation and improve neurological function. Although much remains to be learned, the gut microbiome has become one of the most promising frontiers in autism research, providing new insights into how the immune system, intestinal microbes, and the brain function as an integrated biological network.
*Treg (Regulatory T cell) phenotype is the specific set of physical and molecular characteristics that define this specialized immune cell. Their primary role is to suppress immune responses, prevent autoimmunity, and maintain tolerance to harmless antigens.
